Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on June 26, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Dr. Randal W. Scott exited BridgeBio’s Board after completing his Class I director term on June 22, 2026.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Dr. Randal W. Scott exited BridgeBio’s Board after completing his Class I director term on June 22, 2026
- Resignation not related to disagreements over operations, policies, or practices
- Board composition changed without a disclosed governance dispute or stated operational impact
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders elected Momtazee, McCormick, and Valantine as Class I directors through the 2029 annual meeting
- Executive compensation received advisory approval, with 152,949,577 votes for and 6,938,080 against
- Annual say-on-pay voting adopted, aligning future compensation votes with the stockholder-preferred one-year frequency
- Deloitte & Touche ratified as independent auditor for fiscal 2026, with 175,420,234 votes for
- Incentive plan expanded by 2,000,000 shares, potentially increasing equity-based compensation capacity and dilution risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.